Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone

Apr 26, 2024Diabetes technology & therapeutics

Starting GLP-1 Treatment with FreeStyle Libre Monitoring May Give More Benefits Than GLP-1 Treatment Alone

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

HbA1c reduction was 2.43% greater in the GLP-1+FSL group compared to the GLP-1 group in the unmatched cohort.

Individuals with type 2 diabetes using GLP-1 RA along with FreeStyle Libre (FSL) experienced a greater reduction in HbA1c compared to those using GLP-1 RA alone.
In the unmatched cohort, the GLP-1+FSL group had an HbA1c reduction of -2.43%, while the GLP-1 group had a reduction of -1.73%.
In the matched cohort, HbA1c reduction was -2.43% for GLP-1+FSL compared to -2.06% for GLP-1 alone.
Greater HbA1c reduction with GLP-1+FSL was observed across various insulin treatment levels and with different types of GLP-1 RA medications.
These findings indicate a potential additional glycemic benefit when combining GLP-1 RA therapy with FSL in adults with poorly controlled type 2 diabetes.

AI simplified

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) therapy provides glycemic benefits to individuals with type 2 diabetes (T2D). However, the effects of GLP-1 RA therapy in combination with FreeStyle Libre systems (FSL) are unknown. This study aimed to compare changes in hemoglobin A1c (HbA1c) between people acquiring GLP-1 with FSL (GLP-1+FSL) versus GLP-1 without FSL (GLP-1).This real-world study used Optum's de-identified Market Clarity Data, a linked electronic health records (EHR)-claims database, and included adults with T2D and HbA1c ≥8% who acquired their first GLP-1 RA medication between 2018 and 2022. GLP-1+FSL subjects acquired their first FSL within ±30 days of their first GLP-1 acquisition. Cohorts were matched 1:5 on baseline insulin therapy, age, sex, baseline HbA1c, and GLP-1 type. Paired changes in HbA1c were compared between unmatched and matched groups at 6 months.The study included 24,724 adults in the unmatched cohort (GLP-1+FSL,= 478; GLP-1,= 24,246). The matched cohort included 478 GLP-1+FSL users and 2,390 GLP-1 users: mean age 53.5 ± 11.8 and 53.5 ± 11.3 years, HbA1c 10.25 ± 1.68% and 10.22 ± 1.69%, respectively. HbA1c reduction was greater in the GLP-1+FSL group compared with the GLP-1 group in the unmatched cohort (-2.43% vs. -1.73%, difference 0.70%,< 0.001, respectively) and in the matched cohort (-2.43% vs. -2.06%, difference 0.37%,< 0.001). GLP-1+FSL vs. GLP-1 treatment was associated with greater HbA1c reduction in the intensive insulin (-2.32% vs. -1.50%), nonintensive insulin (-2.50% vs. -1.74%), and noninsulin group (-2.46% vs. -1.78%), as well as in patients using semaglutide (-2.73% vs. -1.92%) and dulaglutide (-2.45% vs. -1.71%) GLP-1 RA, all< 0.001.Adults with suboptimally controlled T2D, initiating GLP-1 RA with FreeStyle Libre, had greater improvement in HbA1c compared with those treated with GLP-1 RA only. These results suggest an additional glycemic benefit of FSL when used with a GLP-1 RA in T2D treatment. Background and Aim: Methods: Results: Conclusions: n n P P P

Full Text

Full text is available at the source.

View full text (XML) ↗View full text (PDF) ↗View full text ↗

Initiating GLP-1 Therapy in Combination with FreeStyle Libre Provides Greater Benefit Compared with GLP-1 Therapy Alone

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief